In treatment-naive diffuse large B-cell lymphoma (DLBCL) patients, venetoclax, in combination with standard immunochemotherapy (R-CHOP), improved PFS, especially in the BCL2-positive (i.e., detectable by immunohistochemistry (IHC)) subgroup [79,80]. Here, BCL2 is linked to diffuse large B-cell lymphoma.